
Botox for erectile dysfunction is an injectable treatment that uses botulinum toxin to support improved erectile function. The medication is injected directly into the corpora cavernosa - the erectile tissue of the penis - where it temporarily reduces cavernosal smooth-muscle contraction and may facilitate increased penile blood flow during an erection.
Sometimes referred to as penile Botox, penis Botox, or intracavernosal botulinum toxin, this treatment uses the same class of medication commonly associated with cosmetic Botox, but for a very different therapeutic purpose. In erectile dysfunction, the goal is not cosmetic - it is to influence the smooth-muscle activity involved in achieving and maintaining an erection.
In simple terms, an erection requires the blood vessels and smooth muscle within the erectile chambers of the penis to relax so they can fill with blood. This process is supported by parasympathetic ("rest-and-relax") signaling, while sympathetic ("fight-or-flight") activity promotes constriction. With aging and vascular changes, the smooth muscle within the penis may remain more constricted, making it harder for the erectile chambers to fully relax and fill with blood; stress and performance anxiety can further increase this constrictive signaling.
More specifically, sympathetic nerve activity - particularly signaling through the neurotransmitter norepinephrine - promotes contraction of the cavernosal smooth muscle. Botulinum toxin (Botox) inhibits the release of certain neurotransmitters, including norepinephrine. When injected into the corpora cavernosa, it may reduce this adrenergic constriction, allowing greater cavernosal smooth-muscle relaxation and improved penile blood flow.
Botox does not directly produce an erection. Rather, the goal is to reduce one of the signals that keeps erectile tissue constricted, potentially creating a more favorable physiologic environment for achieving and maintaining an erection.
Reduced norepinephrine signaling → Reduced smooth-muscle constriction → Improved cavernosal relaxation → Improved penile blood flow
Clinical research on botulinum toxin for erectile dysfunction is still evolving, but early randomized controlled trials and clinical studies have shown promising results - particularly in men whose ED has not responded adequately to traditional therapies such as PDE5 inhibitors.
Studies have reported improvements in validated measures of erectile function, including SHIM/IIEF scores and Erection Hardness Scores (EHS), as well as objective improvements in penile blood flow measured by Doppler ultrasound. In one randomized placebo-controlled trial of men with ED that was refractory to PDE5 inhibitors, 53% of men treated with botulinum toxin were able to achieve an erection firm enough for penetration at six weeks, compared with one patient in the placebo group.
More recent systematic reviews and meta-analyses have generally supported these findings. A 2025 meta-analysis found that at least 40% of treated patients achieved a clinically meaningful improvement in erectile-function scores, while the pooled randomized-trial data showed a significant improvement in SHIM scores compared with placebo. Another systematic review found improvements in erectile function in approximately 41–57% of patients, with benefits reported for up to six months.
Approximately 41–57% of patients experienced improvement in erectile function in published studies, with benefits reported for up to six months.
Importantly, the evidence remains limited compared with established ED therapies. Studies to date have generally been relatively small and have varied in patient selection, dosing, and treatment protocols. Current European Association of Urology guidelines describe botulinum toxin as promising for men who have not responded to established ED therapies but conclude that the evidence is not yet sufficient to recommend its routine clinical use.
Botox may be considered for select men with erectile dysfunction, particularly when vascular dysfunction or increased blood vessel constriction (increased cavernosal smooth-muscle tone) may be limiting penile blood flow. It may also be considered for men who have had an inadequate or diminishing response to oral ED medications such as sildenafil (Viagra®) or tadalafil (Cialis®).
Potential candidates may include men with:
Because the underlying causes of ED vary, appropriate evaluation and patient selection are important before considering Botox treatment.
Treatment begins with an evaluation to determine the likely causes of your erectile dysfunction and whether Botox is appropriate for your specific ED profile.
Botulinum toxin is injected directly into the corpora cavernosa, the erectile chambers of the penis. Local or topical anesthetic may be used for comfort, and the injections themselves typically take only several minutes to complete.
Penile Botox requires little to no downtime, and most patients can return to normal daily activities shortly after treatment. Temporary tenderness, bruising, or swelling at the injection site may occur.
The effects of Botox begin to develop in the first several weeks, and some men may start to notice improvements in erectile response, firmness, or fullness.
Improvements in erectile function may continue to develop as the treatment reaches its fuller effect.
Published studies suggest that improvements may persist for several months, with some studies reporting benefits for up to approximately six months. Individual duration and degree of response vary.
Yes. Botox may be particularly complementary to PDE5 inhibitors such as sildenafil or tadalafil. Studies in men who responded inadequately to ED medications have found improved erectile function after receiving intracavernosal botulinum toxin (Botox) treatment.
Botox may also be used alongside:
Treatment combinations are individualized based on the underlying causes of ED and prior treatment response.
Botulinum toxin has a long history of FDA-approved use for a variety of medical and cosmetic conditions. However, Botox is not FDA-approved specifically for the treatment of erectile dysfunction; its use for ED is considered off-label and remains investigational.
Clinical studies of intracavernosal botulinum toxin have generally reported good tolerability, although research remains limited. Potential side effects include temporary pain or tenderness, bruising, swelling, or bleeding at the injection site. As with any medical treatment, appropriate dosing, patient selection, and evaluation for contraindications are important.
Performance Men's Health provides advanced evaluation and treatment for erectile dysfunction in Bellevue and throughout Seattle and the greater Puget Sound region.
Other Treatments
Explore more of what we offer.
Frequently Asked Questions
No. Botox is not FDA-approved specifically for erectile dysfunction. Its use for ED is considered off-label and remains investigational.
Most patients tolerate penile Botox well. Topical or local anesthetic may be used to minimize discomfort during the brief injection procedure.
Published studies suggest benefits may persist for approximately 3 months, with some reporting benefits up to 6 months.
Effects develop gradually. Men generally notice benefits within 5 days to 2 weeks, with improvement often continuing over subsequent weeks.
Yes. Botox has been studied specifically in men with difficult-to-treat ED who did not respond adequately to PDE5 inhibitors or even Trimix injections. In a randomized trial of 176 such men, up to 40% were able to resume satisfactory sexual activity after Botox treatment. In another placebo-controlled trial of men who had failed PDE5 inhibitors, 53% of Botox-treated patients achieved an erection firm enough for penetration at six weeks, compared with only one patient receiving placebo.
Yes. Botox may be incorporated into a multimodal ED treatment plan that includes shockwave therapy, PRP/P-Shot®, oral medications, or other therapies when clinically appropriate.
Studies of Botox for ED have reported measurable increases in stretched penile length as a secondary treatment effect. In a randomized, placebo-controlled trial of 176 men, researchers objectively measured penile dimensions and found significant increases in stretched penile length after Botox treatment, with improvements persisting at six months. The study did not find a significant increase in penile girth. Botox for ED is intended to improve erectile function and blood flow - not as a primary penile enlargement treatment.
Botox for ED targets smooth-muscle signaling within the erectile tissue rather than the sensory nerves responsible for penile sensation. Published ED studies have not established loss of sensation or orgasm as a treatment side effect.
Trimix is used as needed to pharmacologically produce an erection. The medication is self-delivered 15 minutes prior to sexual activity. Botox has a longer-lasting effect on smooth-muscle constriction and the ability of blood vessels to expand and fill with blood. Botox is intended to support the body's erectile response and improve responsiveness to medication.
Botox is not appropriate for every patient. Medical history, medications, underlying causes of ED, and potential contraindications should be evaluated before treatment.
Schedule a consultation with the Performance Men's Health team.